Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 13/20 | 0.41 |
| ▸ | S100A9 | P06702 | 6/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16248209 | 1.00 | CCR4 (0.41) | CCR4S100A9CCR5 | |
| SCHEMBL16235307 | 0.84 | CCR4 (0.62) | CCR4CCR5 | |
| SCHEMBL16235480 | 0.75 | CCR4 (0.67) | CCR4S100A9 | |
| SCHEMBL16235468 | 0.72 | S100A9 (0.64) | CCR4S100A9 | |
| SCHEMBL16248231 | 0.63 | S100A9 (0.58) | CCR4S100A9 | |
| SCHEMBL17472732 | 0.63 | S100A9 (0.58) | CCR4S100A9 | |
| SCHEMBL16248230 | 0.63 | S100A9 (0.58) | CCR4S100A9 | |
| SCHEMBL16235019 | 0.63 | S100A9 (0.61) | CCR4S100A9 | |
| SCHEMBL16235482 | 0.61 | S100A9 (0.55) | CCR4S100A9 | |
| SCHEMBL16235220 | 0.59 | S100A9 (0.67) | CCR4S100A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220378763-A1 | COMPOUND FOR TREATMENT OF ACUTE INFLAMMATION IN THE MYOCARDIUM | CALPROTECT AB (SE) | 2022-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220378763-A1 | COMPOUND FOR TREATMENT OF ACUTE INFLAMMATION IN THE MYOCARDIUM | TNNT2, TNNI3, HMGB1 | CCR4 2451/4885S100A9 330/4885CCR5 976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.